KB14A (anti-β glucan)

About KBio

KBio is pioneering a plant-based manufacturing platform, RP3, designed to produce monoclonal antibodies and other biologics more rapidly, scalably, and sustainably than conventional CHO cell systems. The company has a preclinical pipeline targeting high-demand areas like invasive fungal infections and immuno-oncology, with programs such as KB14A for aspergillosis and candida. As a private, pre-revenue biotech, KBio's strategy is built on validating its platform through internal pipeline advancement and strategic partnerships to disrupt the biologics production landscape.

Therapeutic Areas